Potential Drug Target for RDH16: NAD+-Dependent Enzyme (G8608)

Target Name: RDH16

NCBI ID: G8608

RDH16

Potential Drug Target for RDH16: NAD+-Dependent Enzyme

RDH16 (Microsomal NAD(+)-dependent retinol dehydrogenase 4) is a protein that is expressed in various tissues and cells in the body. It is a member of the NAD+-dependent enzymes family 16, which includes proteins that are involved in the metabolism of nucleotides, including NAD+. NAD+ is a crucial coenzyme that plays a vital role in various cellular processes, including energy metabolism, signaling pathways, and DNA replication. The function of RDH16 is not well understood, but it is believed to be involved in the regulation of cellular processes, such as cell growth, differentiation, and survival.

Drug targeting

RDH16 is a potential drug target because of its unique structure and the roles that it plays in various cellular processes. One of the main reasons for its potential as a drug target is its NAD+-dependent function, which makes it a promising target for drugs that target NAD+-dependent pathways. NAD+ is a crucial coenzyme that is involved in the metabolism of various molecules, including drugs that are used to treat various diseases, such as cancer, cardiovascular disease, and neurological disorders. By targeting NAD+-dependent pathways, drugs can inhibit the function of RDH16 and disrupt its role in these cellular processes, leading to potential therapeutic benefits.

Another potential reason for RDH16's potential as a drug target is its unique structure. RDH16 is a protein that is composed of approximately 250 amino acid residues and has a calculated molecular mass of 33.9 kDa. It has a distinct N-terminus that is involved in its NAD+-dependent function and a C-terminus that is involved in its catalytic activity. The N-terminus of RDH16 contains a conserved domain that is known as the NAD+-binding domain, which is responsible for the NAD+ dependence of the enzyme's function. This domain is located at the base of the N-terminus and consists of a short alpha-helices and a long beta-sheet.

The C-terminus of RDH16 contains a catalytic domain that is known as the active site domain. This domain is located at the center of the protein and is responsible for the binding of various molecules, including NAD+ and other cofactors. The active site domain has a unique structure that is composed of a nucleotide-binding oligomerization (NBO) domain and a structural domain that is responsible for the binding of various ligands, including NAD+.

Expression and regulation

RDH16 is expressed in various tissues and cells in the body, including the liver, pancreas, and gastrointestinal tract. It is also expressed in various cell types, including muscle, nerve, and epithelial cells. The expression of RDH16 is regulated by various factors, including DNA replication, cell growth, and stress.

DNA replication is a critical factor that regulates the expression of RDH16. RDH16 is a DNA-binding protein and is involved in the regulation of DNA replication and gene expression. It has been shown that RDH16 plays a role in the regulation of DNA replication, including the proofreading of DNA errors and the repair of DNA damage.

Cell growth is another critical factor that regulates the expression of RDH16. RDH16 is involved in the regulation of cellular processes that are related to cell growth, such as cell division, migration, and invasion. It has been shown that RDH16 plays a role in the regulation of cells

Protein Name: Retinol Dehydrogenase 16

Functions: Oxidoreductase with a preference for NAD. Oxidizes all-trans-retinol, 9-cis-retinol, 11-cis-retinol and 13-cis-retinol to the corresponding aldehydes (PubMed:10329026, PubMed:12534290, PubMed:9677409). Has higher activity towards CRBP-bound retinol than with free retinol (PubMed:12534290). Oxidizes also 3-alpha-hydroxysteroids. Oxidizes androstanediol and androsterone to dihydrotestosterone and androstanedione. Can also catalyze the reverse reaction (PubMed:10329026, PubMed:9677409, PubMed:29541409)

The "RDH16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RDH16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets